Catalent Licenses Excelimmune’s Antibody Combination Therapy Platform
Catalent’s licensing of Excelimmune’s antibody combination therapy platform can enable the manufacture of multiple recombinant antibodies in a single batch culture.
Catalent has signed a licensing agreement with Excelimmune to access its antibody combination therapy technology platform, which has the potential to enable a consistent and cost-effective method to manufacture multiple recombinant antibodies or other recombinant proteins in a single batch culture, the company reported on July 7.
Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs. Catalent will also leverage its proprietary GPEx technology to help enable that development.
Excelimmune's antibody combination expression system is based on the use of stable pools of cells generated by multiple directed gene insertions, instead of clonal cell lines. This attribute contributes to a quick, stable, and flexible culture system for mixtures of cells producing different antibodies. This technology has the potential to pave the way for more consistent, cost-effective production of antibody combinations, which will allow complex antibody therapeutics to gain greater accessibility to the clinic.
Source: Catalent
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
